Immunic, Inc. Announces Special Meeting of Stockholders on March 4, 2024

TL;DR

<b>Immunic, Inc. will hold a virtual special meeting of stockholders on March 4, 2024, urging all shareholders to vote by proxy.</b>

AI Summary

IMMUNIC, INC. (IMUX) filed a Proxy Statement (DEF 14A) with the SEC on February 5, 2024. Immunic, Inc. is holding a special meeting of stockholders on March 4, 2024, at 10:00 a.m. Eastern Standard Time. The meeting will be conducted virtually via the Internet at https://web.lumiagm.com/276702602. No physical meeting will be held; the meeting will be conducted exclusively by webcast. Stockholders are urged to vote their shares regardless of attendance, with options for Internet, telephone, or mail proxy voting. The filing is a Definitive Proxy Statement (DEF 14A) for the special meeting.

Why It Matters

For investors and stakeholders tracking IMMUNIC, INC., this filing contains several important signals. This DEF 14A filing provides essential details for stockholders to participate in and vote at the upcoming special meeting, crucial for corporate governance decisions. The virtual format necessitates clear instructions for remote attendance and voting, ensuring all shareholders have the opportunity to exercise their rights.

Risk Assessment

Risk Level: low — IMMUNIC, INC. shows low risk based on this filing. The filing is a routine proxy statement for a special meeting, with no immediate financial or operational risks disclosed.

Analyst Insight

Stockholders should review the proxy materials to understand the agenda and vote their shares to ensure their voice is heard in corporate decisions.

Key Numbers

• March 4, 2024 — Special Meeting Date (Date of the special meeting of stockholders.)
• 10:00 a.m. EST — Special Meeting Time (Time of the special meeting of stockholders.)

Key Players & Entities

• Immunic, Inc. (company) — Registrant and filer of the proxy statement.
• March 4, 2024 (date) — Date of the special meeting of stockholders.
• 10:00 a.m. Eastern Standard Time (time) — Time of the special meeting of stockholders.
• https://web.lumiagm.com/276702602 (url) — Webcast link for the virtual special meeting.
• DEF 14A (document_type) — Form type of the filing.
• 1200 Avenue of the Americas, Suite 200 New York, New York 10036 (address) — Business and mailing address of Immunic, Inc.

FAQ

Industry Context

Immunic, Inc. operates in the pharmaceutical preparations industry, focusing on developing novel therapies.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.

What Investors Should Do

1. Review the proxy statement for details on proposals to be voted on.
2. Vote your shares by the deadline using the provided Internet, telephone, or mail options.
3. Ensure your proxy is submitted correctly to be represented at the virtual meeting.

Key Dates

• 2024-03-04: Special Meeting of Stockholders — To conduct company business and vote on proposals.

Year-Over-Year Comparison

This is a DEF 14A filing for a special meeting, distinct from regular periodic filings.

Key Financial Figures

• $0.0001 — r of authorized shares of common stock, $0.0001 par value per share (the &ldquo;Common

Filing Documents

• e619216_def14a-immunic.htm (DEF 14A) — 642KB
• image_001.jpg (GRAPHIC) — 1KB
• image_002.jpg (GRAPHIC) — 6KB
• image_003.jpg (GRAPHIC) — 5KB
• 0001193805-24-000129.txt (&nbsp;) — 660KB

SECURITY OWNERSHIP

SECURITY OWNERSHIP 25 OTHER MATTERS 27 WHERE YOU CAN FIND ADDITIONAL INFORMATION 27 IMMUNIC, INC. PROXY STATEMENT For the 2024 Special Meeting of Stockholders to be held on March 4, 2024 . The information provided in the &ldquo;Questions and Answers&rdquo; format below is for your convenience only and is merely a summary of the information contained in this proxy statement. You should read the entire proxy statement carefully. QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND SPECIAL MEETING Why am I receiving these materials? This proxy statement and the enclosed form of proxy are furnished in connection with the solicitation of proxies by our board of directors for use at the 2024 Special Meeting of stockholders of Immunic, Inc., a Delaware corporation, and any postponements or adjournments thereof. The Special Meeting will be held on March 4, 2024 at 10:00 a.m. Eastern Standard time, virtually via the Internet at https://web.lumiagm.com/276702602. No physical meeting will be held. Stockholders are invited to attend the virtual Special Meeting and are requested to vote on the items of business described in this proxy statement. The proxy statement is being mailed on or about February 2, 2024 to all stockholders entitled to vote at the Special Meeting. What am I voting on? You are being asked to vote on four proposals: &middot; The approval of an amendment of our Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of Common Stock from 130,000,000 shares to 500,000,000; &middot; The approval of an amendment to the 2021 Employee Stock Purchase Plan to increase in the number of shares of Common Stock reserved for delivery by 1,000,000 shares to a total of 1,200,000 shares; &middot; The approval of an amendment to the Existing 2019 Omnibus Plan to increase the number of shares of Common Stock authorized for issuance by 9,100,000 shares to a total of 19,448,871 shares; and &middot; The approval of

View Full Filing

View this DEF 14A filing on SEC EDGAR